ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
OptiNose Inc

OptiNose Inc (OPTN)

1.01
-0.05
(-4.72%)
Closed July 22 4:00PM
1.04
0.00
( 0.00% )
Pre Market: 4:25AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.04
Bid
1.01
Ask
1.15
Volume
-
0.00 Day's Range 0.00
0.80 52 Week Range 2.10
Market Cap
Previous Close
1.04
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
746,144
Shares Outstanding
113,038,726
Dividend Yield
-
PE Ratio
-3.31
Earnings Per Share (EPS)
-0.31
Revenue
70.99M
Net Profit
-35.48M

About OptiNose Inc

OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation ... OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation delivery system, to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
OptiNose Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OPTN. The last closing price for OptiNose was $1.04. Over the last year, OptiNose shares have traded in a share price range of $ 0.80 to $ 2.10.

OptiNose currently has 113,038,726 shares outstanding. The market capitalization of OptiNose is $117.56 million. OptiNose has a price to earnings ratio (PE ratio) of -3.31.

OPTN Latest News

Expanded Access to XHANCE with Addition to National Commercial Formularies

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.21-16.81.251.251.018849451.09334006CS
4-0.04-3.70370370371.081.30.997797571.10234007CS
120.2125.30120481930.831.3350.810457461441.10742381CS
26-0.39-27.27272727271.432.10.88792151.21442363CS
52-0.08-7.142857142861.122.10.85937231.21982361CS
156-1.67-61.62361623622.714.30.84030631.64931618CS
260-4.83-82.28279386715.8711.660.83922222.98805243CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NMHINatures Miracle Holding Inc
$ 0.9935
(183.86%)
5.41M
GPGreenPower Motor Company Inc
$ 1.79
(59.11%)
4
FEIMFrequency Electronics Inc
$ 13.30
(31.68%)
40.96k
LGHLWLion Group Holding Ltd
$ 0.0093
(30.99%)
156
ENGENGlobal Corp
$ 2.22
(29.82%)
258
RNAZTransCode Therapeutics Inc
$ 0.3395
(-57.16%)
263.82k
MIRAMIRA Pharmaceuticals Inc
$ 3.69
(-26.35%)
659.83k
NUKKNukkleus Inc
$ 0.3892
(-21.85%)
116.87k
CMAXCareMax Inc
$ 4.08
(-21.39%)
159.5k
XCURExicure Inc
$ 0.4119
(-17.59%)
5.36k
NMHINatures Miracle Holding Inc
$ 0.9935
(183.86%)
5.41M
LIFWMSP Recovery Inc
$ 0.6287
(24.08%)
2.68M
BREABrera Holdings PLC
$ 0.6661
(-9.63%)
1.53M
SLNASelina Hospitality PLC
$ 0.0347
(-6.22%)
964.09k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.41
(0.84%)
795.85k

OPTN Discussion

View Posts
glenn1919 glenn1919 2 months ago
OPTN........................https://stockcharts.com/h-sc/ui?s=OPTN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
OPTN new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
OPTN under $2
πŸ‘οΈ0
Awl416 Awl416 4 months ago
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
OPTN 10Q due March 7
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
OPTN new 52 week low
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
nice volume
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
dip
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN
OPTINOSE INC
Last [Tick] $6.29[+]
Change Up $0.58
% Change Up 10.1576%
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN
5.87 [+] up tick
0.16 (2.8021%)
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
Press Release: Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
BY Dow Jones & Company, Inc.β€” 7:29 AM ET 08/04/2020

Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

Company reports second quarter 2020 XHANCE net revenue of $10.3 million

Second quarter 2020 XHANCE prescriptions increased 84% from second quarter 2019 (My emphasis- MG)

Conference call and webcast to be held today at 8:00 a.m. Eastern Time

YARDLEY, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Optinose ( OPTN ) , a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2020, and provided operational updates.

"XHANCE prescription volume continued to grow in the second quarter, which was impressive given the major disruptions to patient volumes and care pathways within ENT and allergy physician practices," stated CEO Peter Miller. "XHANCE had exceptionally strong market share growth, demonstrating remarkable resilience, as we successfully adapted our business to the COVID-19 environment. We are excited by the potential for XHANCE to continue to grow and recently announced a co- promotion with kaléo that will amplify our effort. We look forward to a strong partnership that we believe can have meaningful impact."
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN 5.72 +12%
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN

AUG 04
OPTN to announce Q2 earnings (Confirmed)

πŸ‘οΈ0
ssmmss ssmmss 4 years ago
It amazes me that a company like this, sitting on $140M in cash and a market cap of only $240M and a PT of $20 is going under the radar. Once the street gets word of it, SP will go to $15 which is its current market value TODAY.
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN Heading back up
Another Covid play.
I am looking for a breakout, here.
MG
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN Company website: https://www.optinose.com/
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
BY GlobeNewswire β€” 4:15 PM ET 07/08/2020

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions, to co-promote XHANCE® (fluticasone propionate) exhalation nasal spray 93 mcg, for the treatment of nasal polyps in patients 18 years or older in the United States.

"We are excited to partner with kaléo and leverage the strong relationships they have built with physicians in our target audience," said Vic Clavelli, Chief Commercial Officer of Optinose (OPTN). "This co-promotion partnership will build upon that strength and help us grow our target audience’s appreciation for all XHANCE has to offer by efficiently broadening and deepening our promotional reach. I am confident that the kaléo sales team will complement and amplify the efforts of the Optinose (OPTN) team starting in the fourth quarter of this year."

β€œOur team is pleased to collaborate with Optinose on the promotion of XHANCE,” said Omar Khalil, kaléo’s General Manager of Allergy and Pediatrics. β€œThe deep relationships we have developed over the years with allergists makes kaléo a natural fit for this innovative product that serves the needs of patients with this condition.”

Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency. The audience includes nearly 6,000 prescribers about half of whom are outside of the current Optinose (OPTN) called-on universe of approximately 10,000 healthcare professionals.

About Optinose (OPTN)
Optinose ( OPTN ) is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN Ford Equity Research upgrades OPTINOSE INC from 4 to 3.
BY Investars Analyst Actions - 3:20 PM ET 07/10/2020

On July 10, 2020 Ford Equity Research upgraded OPTINOSE INC (OPTN ) from 4 to 3.
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN Refinitiv/Verus upgrades OPTINOSE INC from SELL to BUY.
BY Investars Analyst Actions - publicβ€” 3:01 PM ET 07/13/2020

On July 13, 2020 Refinitiv/Verus upgraded OPTINOSE INC (OPTN) from SELL to BUY.
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN Small cap ($275M) beginning study of its nasal spray for treatment of covid 19 in the sinus cavity, where the virus is thought to begin its passage.
Finances and share structure good. Anal rating and 'tute ownership good.
Two recent upgrades to BUY.
$19 PT Piper

MG
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTN
OPTINOSE INC
6.238 Up 1.408 (29.1511 %) AS OF 11:36:42AM ET 07/17/2020
πŸ‘οΈ0
MiamiGent MiamiGent 4 years ago
OPTI Just got in this morning @ 5.63
Currently 5.98
Nascent Covid 19 play

MG
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock